[What's new in the management of endometrial cancer? Update on the new European recommendations for 2021]

Gynecol Obstet Fertil Senol. 2021 Sep;49(9):691-697. doi: 10.1016/j.gofs.2021.03.005. Epub 2021 Mar 20.
[Article in French]

Abstract

The new European guidelines for the management of patients with endometrial cancer were published in early 2021. These recommendations are joint to the three European Learned Societies of Gynecologic Oncology (ESGO), Radiation Therapy and Oncology (ESTRO) and Anatomical Pathology (ESP). On behalf of the French Society of Gynecologic Oncology (SFOG), we wish to bring to the knowledge of the French-speaking readership the main measures for the management of patients which represent an advance compared to the 2016 recommendations. The new European recommendations for the management of patients with endometrial cancer emphasize the generalization of micro-satellite instability (MSI) or immunohistochemical analysis of MMR system proteins for all patients. Also, the classification into 4 prognostic risk groups integrates data from molecular analysis (p53, MSI, POLE) to guide initial surgical management as well as adjuvant treatment modalities. The indocyanine green sentinel node procedure has also become the reference technique for FIGO I and II lymph node staging regardless of histological type. It should be remembered that management should be provided in a specialized institution by a team specialized in the management of gynecological cancers, particularly for high-risk and/or advanced cancer patients.

Keywords: Analyse moléculaire; Cancer endomètre; Endometrial cancer; European; Européennes; Ganglion sentinelle; Guidelines; Indocyanine; Molecular analysis; Recommandations; Sentinel lymph node.

Publication types

  • Review

MeSH terms

  • Endometrial Neoplasms* / surgery
  • Female
  • Humans
  • Indocyanine Green
  • Neoplasm Staging
  • Sentinel Lymph Node Biopsy
  • Sentinel Lymph Node* / pathology

Substances

  • Indocyanine Green